ReviewJAAD international2026
Survival after lymph node dissection, radiotherapy, and combined treatment in sentinel node-positive stage IIIA Merkel cell carcinoma: A systematic review and meta-analysis.
Review in JAAD international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Merkel cell carcinoma (MCC) has a high risk of regional lymphatic metastasis. In cases of lymphatic micrometastasis, an evidence-based clinical approach is missing. Objective: To assess survival outcomes following complete lymph node dissection (CLND), radiation (RTX), or CLND plus RTX (CLND + RTX) in patients with stage IIIA MCC. Methods: A systematic search was conducted in MEDLINE, Embase, and the Cochrane Library. Pooled survival rates were calculated using random-effects models. Comparative effectiveness of interventions was assessed via network meta-analysis. Results: Eight studies, including 1825 patients, were analyzed. Pooled 1- and 3-year survival rates (overall survival and MCC-specific survival) following CLND (regardless of RTX) were 93% (95% CI, 89%-96%) and 71% (95% CI, 64%-77%), showing no significant difference compared with patients without CLND. Furthermore, relative risk ratios comparing RTX (regardless of CLND status) with no RTX demonstrated no significant differences for overall survival at either 1 or 3 years. Finally, a network meta-analysis also did not show superiority among CLND only, RTX only, and CLND + RTX in patients with stage IIIA MCC. Limitations: The limited number of observational studies, data heterogeneity, missing data regarding immunotherapies, and low evidence levels according to the GRADE restrict definitive conclusions. Conclusions: Findings underscore the need for large, prospective clinical trials to define optimal treatment strategies for patients with stage IIIA MCC. PROSPERO number: CRD42025636348.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.